Korea, which is regarded as an endemic area of HBV infection, a nationwide survey revealed an HBsAg prevalence of 5.1% in men and 4.1% in women. 4 Reactivation of HBV has been well documented in infected patients receiving chemotherapy for cancer
Search Results
Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im, and Jung-Hwan Yoon
James M. Hoffman, Donald K. Baker, Scott C. Howard, Joseph H. Laver, and Jerry L. Shenep
Various programs are ongoing to promote the implementation of EHRs and CPOE, including federal incentives that will become available in 2011. 4 Specific data on the use of CPOE for chemotherapy are limited, but CPOE for chemotherapy seems to lag behind
John M. Salsman, Steven M. Grunberg, Jennifer L. Beaumont, Miriam Rogers, Diane Paul, Marla L. Clayman, and David Cella
Nausea and vomiting are two of the most common and debilitating side-effects of chemotherapy and can result in significant morbidity and adversely impact patient quality of life. 1 – 4 Nausea and vomiting secondary to chemotherapy may lead to
George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, and Alva B. Weir III
guidelines underwent substantial revisions. The purpose of these guidelines is 2-fold: 1) to operationalize the evaluation and treatment of anemia in adult patients with cancer, with an emphasis on those with anemia who are receiving concomitant chemotherapy
Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell
Background Over the past 50 years, substantial reductions in early breast cancer mortality have been documented due to a combination of earlier detection and to advances in adjuvant treatment. 1 – 4 In particular, adjuvant chemotherapy has
Jerome Kim and Arti Hurria
of Determining Potential Toxicities A major concern when treating geriatric patients with cancer is the risk for chemotherapy-related toxicities. Although trials show that chemotherapy is effective in patients with “good” functional status, the same
Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
primarily treated by surgery, followed by adjuvant chemotherapy under certain conditions. Adjuvant treatment of stage II colon cancer is controversial 3 and mostly restricted to high-risk patients. 4 – 7 However, adjuvant chemotherapy has been widely
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease
Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin, and Harold J. Burstein
+ breast cancer; and HER2-directed therapies for HER2-amplified breast cancer. 15 , 16 However, despite the heterogeneity of breast cancer, almost all patients with MBC will receive chemotherapy at some point. Compared with patients who have other solid
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao
Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare
